Supriya Lifescience Limited — PPTs, 24-01-2025: Investor Presentation

**Q3 & 9M FY25 Investor Presentation Summary**

**Financial Highlights:** Supriya Lifescience achieved notable revenue growth, reporting ₹1,856.5 Mn for Q3 FY25, marking a 33% increase from the previous year, and ₹5,123.8 Mn for the nine-month period, a 24% year-on-year rise. EBITDA reached ₹659.5 Mn for Q3, up 59% YoY, with EBITDA margins improving to 35.5%. Profit after tax (PAT) surged to ₹467.8 Mn, reflecting a 57% increase.

**Strategic Initiatives and Growth Drivers:** The company has advanced its research capabilities with two new R&D centers focusing on lifecycle management and product development, which are pivotal for expanding its API portfolio, particularly in anti-diabetic and anesthetic segments.

**Business Developments:** Supriya announced a significant contract in the CMO sector, partnering with a leading European firm for a decade-long agreement expected to yield peak revenues of ₹60 Cr per year from FY27 onwards.

**Market Position and Competitive Advantage:** With a strong export presence in over 120 countries and a diverse customer base of 1,500+, the company continues to minimize customer concentration risks while enhancing its market share in North America and other new geographies.

**Investor Implications:** The robust financial performance, strategic expansion into new markets, and significant R&D investments provide a solid foundation for growth, signaling a positive outlook for potential investors.